Two: GLP-1 agonists (semaglutide, tirzepatide) for metabolic and weight indications, and bremelanotide (PT-141) for HSDD in premenopausal women
In the SURMOUNT-1 trial, tirzepatide 15 mg produced a mean weight reduction of 22.5% over 72 weeks in adults without diabetes, highlighting the potential value of multi-receptor metabolic therapy
It was slight, but it definitely made me do a double-take
Zhou CQ, Li SS, Chen ZM, Li FQ, Lei P, Peng GG
The occurrence of ferroptosis in mature erythrocytes has not been confirmed and it seems quite challenging, since ferroptosis studies suffer from the lack of well-established markers and evaluation of this cell death requires a complex approach with identification of typical cellular and subcellular morphological alterations, genetic hallmarks, biochemical changes, expression of certain ferroptosis-related proteins, etc